Cell Source, Inc.

Equities

CLCS

US15114L1044

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:54:58 2024-05-09 pm EDT			5-day change	1st Jan Change
0.0008 ^USD	+300.00%		+300.00%	-99.83%

Mar. 22	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
2023	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Cell Source, Inc. Announces Board Appointments

July 06, 2015 at 09:08 am EDT

Cell Source, Inc. announced that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board. Dr. Negrin has served as the President of the American Society of Bone and Marrow Transplantation and the International Society of Cellular Therapy.

Latest news about Cell Source, Inc.

Cell Source, Inc. announced that it has received $4.76017 million in funding	Mar. 21	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-19	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-08-23	CI
Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-08-08	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-08	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-12-02	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-11-02	CI
Cell Source, Inc. Announces Board Resignations	22-07-21	CI
Cell Source, Inc. Announces Resigation of Itamar Shimrat as A Director	22-05-06	CI
Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Cell Source, Inc. Appoints George Verstraete as Member	22-03-11	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-15	CI
Cell Source, Inc. Appoints Darlene Soave to its Board of Directors, Effective May 25, 2021	21-04-01	CI
USPTO Issues New Patents for Cell Source's Veto Cell Technology	21-03-19	CI
Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials	21-03-12	CI
Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory Board	21-02-25	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI
Cell Source, Inc. Announces Resignation of Yoram Drucker as Director	19-04-19	CI

Chart Cell Source, Inc.

Duration

Period

More charts

Company Profile

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CELL SOURCE, INC.	-99.83%	32.82K
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs